Literature DB >> 11745228

Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders.

O Laccourreye1, D Veivers, S Hans, M Ménard, D Brasnu, H Laccourreye.   

Abstract

BACKGROUND: The current studies documented the results achieved with chemotherapy alone with curative intent in a series of 67 patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders after a platin-based induction chemotherapy regimen.
METHODS: Group I consisted of 36 patients with tumors originating from the glottis. Group II consisted of 31 patients with tumors originating from sites within the pharyngolarynx other than the glottis. A minimum of 3 years of follow-up was achieved. Statistical analyses of survival, local control, lymph node control, distant metastasis, and second primary tumor rates were based on the Kaplan-Meier life-table method. Laryngeal preservation rates and local control rates are presented.
RESULTS: The 5-year actuarial survival estimate was 85.1% in Group I patients and 54.8% in Group II patients. Survival was statistically more likely to be reduced in Group II patients compared with Group I patients (P = 0.01). The 5-year actuarial local control estimate was 65.7% in Group I patients and 37.5% in Group II patients. Local failure was statistically more likely to occur in Group II patients compared with Group I patients (P = 0.02). Local control rates after salvage treatment were 100% in Group I patients and 83% in Group II patients. Laryngeal preservation rates after salvage treatment were 100% in Group I patients and 64% in Group II patients. The 5-year actuarial lymph node control estimate was 90% in Group I patients and 73.7% in Group II patients. Lymph node failure was statistically more likely to occur in Group II patients compared with Group I patients (P = 0.04). The 5-year actuarial estimate for patients without distant metastasis was 100% in Group I patients and 90% in Group II patients. Distant metastasis was statistically more likely to occur in Group II patients compared with Group I patients (P = 0.03). The 10-year actuarial estimate for patients without metachronous second primary tumors was 56.4% in Group I and 46.1% in Group II.
CONCLUSIONS: The current report 1) contradicts the old dogma of nonchemocurability for invasive squamous cell carcinoma of the upper aerodigestive tract and 2) suggests that the use of a platin-based chemotherapy-alone regimen with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx who are classified as T1-T4N0M0 complete clinical responders after receiving an induction chemotherapy regimen is best indicated when the tumor originates from the glottis. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745228     DOI: 10.1002/1097-0142(20010915)92:6<1504::aid-cncr1475>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Results of an organ preservation protocol with induction chemotherapy and radiotherapy in patients with locally advanced laryngeal carcinoma.

Authors:  Xavier León; Antonio López-Pousa; Manuel de Vega; César Orús; Manuel de Juan; Miquel Quer
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-02-18       Impact factor: 2.503

2.  [Recent advances in the treatment of laryngeal and hypopharyngeal carcinoma].

Authors:  H E Eckel
Journal:  HNO       Date:  2012-01       Impact factor: 1.284

3.  Chemotherapy alone for organ preservation in advanced laryngeal cancer.

Authors:  Vasu Divi; Francis P Worden; Mark E Prince; Avraham Eisbruch; Julia S Lee; Carol R Bradford; Douglas B Chepeha; Theodoros N Teknos; Norman D Hogikyan; Jeffrey S Moyer; Christina I Tsien; Susan G Urba; Gregory T Wolf
Journal:  Head Neck       Date:  2010-08       Impact factor: 3.147

4.  Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.

Authors:  F Christopher Holsinger; Merrill S Kies; Eduardo M Diaz; Ann M Gillenwater; Jan S Lewin; Lawrence E Ginsberg; Bonnie S Glisson; Adam S Garden; Nebil Ark; Heather Y Lin; J Jack Lee; Adel K El-Naggar; Waun Ki Hong; Dong M Shin; Fadlo R Khuri
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

5.  Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.

Authors:  F Christopher Holsinger; Heather Y Lin; Vincent Bassot; Ollivier Laccourreye
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

6.  Curative treatment can be an option for patients with metastatic squamous cell cancer of the head and neck.

Authors:  Clémence Guenne; Jérôme Fayette; Alain Cosmidis; Carine Fuchsmann; Sophie Tartas; Véronique Favrel; Philippe Céruse
Journal:  Drug Des Devel Ther       Date:  2014-12-12       Impact factor: 4.162

Review 7.  Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.

Authors:  Remco de Bree; Gregory T Wolf; Bart de Keizer; Iain J Nixon; Dana M Hartl; Arlene A Forastiere; Missak Haigentz; Alessandra Rinaldo; Juan P Rodrigo; Nabil F Saba; Carlos Suárez; Jan B Vermorken; Alfio Ferlito
Journal:  Head Neck       Date:  2017-08-17       Impact factor: 3.147

8.  Systemic therapy strategies for head-neck carcinomas: Current status.

Authors:  Thomas K Hoffmann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

9.  Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.

Authors:  A Lièvre; H Blons; A M Houllier; O Laccourreye; D Brasnu; P Beaune; P Laurent-Puig
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.